Phase 3Terminated
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer Who Are Chemotherapy-Naïve
- Sponsor
- Cell Genesys (Industry)
- Enrolment
- 626 enrolled
- Conditions
- Prostate Cancer
- Interventions
- Immunotherapy with allogeneic prostate vaccine; Chemotherapy (Taxotere and prednisone)
- Ages
- adults, older adults
- Registry
- NCT00089856
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.
Primary outcomes
- Survival
History
Last registry update
Primary completion
Registered
Started